Tepezza Litigation Group

Tepezza was approved in 2020 for the treatment of thyroid eye disease. Unfortunately, it is repeatedly associated with hearing loss, tinnitus with hearing damage, and permanent hearing damage. The group shares litigation developments and discusses strategy, in this emerging litigation.

Group History

The Tepezza Litigation Group was formed at the 2023 Winter Convention. Members have access to a document library and list server. The Group meets at AAJ Annual and Winter conventions and plans to host programs and meetings throughout the year.

Dues: $150 per member annually

Chair

Stacy Hauer | Johnson Becker, PLLC, St. Paul, MN

Molly Wells | Wallace Miller, Chicago, IL